Mobile website
Archive > Volume 25 Issue 5 > 2018,25(5):441-446. DOI:10.3872/j.issn.1007-385X.2018.05.001 Prev Next
Expert Forum
EGFRvⅢ and immunotherapy of glioblastoma multiforme
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] EGFRvIII (epidermal growth factor receptor variant Ⅲ) is the most common mutant of epidermal growth factor receptor,which expresses in over 30% glioblastoma multiforme (GBM). EGFRvIII results from deletion of exon 2-7, leading to its constitutive activation, which is closely related to tumorigenesis, development and poor prognosis of GBM. The unique glycine site on EGFRvIII provides ideal molecular target for immunotherapy, which possess great potential value of killing GBM cell, inhibiting progress and invasion.Encouraging progress has been achieved in peptide/DC vaccine, therapeutic antibody, small molecular inhibitor and adoptive immunotherapy experimentally and clinically. The characteristics of EGFRvIII and the development in its oriented immunotherapy were summarized in this review.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of China（No.81372405, No.81772670）
Clc Number:
